Bermingham Nessan
Insider CIK 1377759 · FSTX Director · NTLA President & CEO, Director · KRRO Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KRRO Korro Bio, Inc. | A Award deriv | 2026-06-10 | 2026-06-11 | 14,677 | — | $0 | 14,677 | SEC↗ |
| KRRO Korro Bio, Inc. | A Award deriv | 2025-06-11 | 2025-06-12 | 6,010 | — | $0 | 6,010 | SEC↗ |
| KRRO Korro Bio, Inc. | A Award deriv | 2024-06-11 | 2024-06-12 | 5,190 | — | $0 | 5,190 | SEC↗ |
| KRRO Korro Bio, Inc. | A Award deriv | 2023-11-03 | 2023-11-07 | 24,712 | — | $0 | 24,712 | SEC↗ |
| KRRO Korro Bio, Inc. | A Award deriv | 2023-11-03 | 2023-11-07 | 67,061 | — | $0 | 67,061 | SEC↗ |
| KRRO Korro Bio, Inc. | A Award | 2023-11-03 | 2023-11-07 | 35,114 | — | $0 | 35,114 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | D To issuer deriv | 2023-03-08 | 2023-03-09 | 20,000 | — | $0 | 0 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | D To issuer deriv | 2023-03-08 | 2023-03-09 | 20,000 | — | $0 | 0 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | D To issuer deriv | 2023-03-08 | 2023-03-09 | 34,111 | — | $0 | 0 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | D To issuer | 2023-03-08 | 2023-03-09 | 6,328 | $7.12 | $45.1K | 0 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | U Tender | 2023-03-08 | 2023-03-09 | 97,547 | $7.12 | $694.5K | 6,328 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | A Award deriv | 2022-06-17 | 2022-06-22 | 20,000 | — | $0 | 20,000 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | A Award deriv | 2021-06-04 | 2021-06-07 | 20,000 | — | $0 | 20,000 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | A Award | 2021-02-01 | 2021-02-02 | 87,000 | — | $0 | 103,875 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | A Award | 2020-11-20 | 2021-08-24 | 16,875 | — | $0 | 16,875 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | A Award deriv | 2020-11-20 | 2020-11-24 | 34,111 | — | $0 | 34,111 | SEC↗ |
| FSTX F-star Therapeutics, Inc. | A Award deriv | 2020-11-20 | 2020-11-24 | 16,875 | — | $0 | 16,875 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2017-12-12 | 2017-12-14 | 292,500 | — | $0 | 292,500 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2017-12-08 | 2017-12-08 | 94,143 | $20.82 | $1.96M | 458,250 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2017-12-07 | 2017-12-08 | 27,566 | $21.46 | $591.6K | 552,393 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2017-12-07 | 2017-12-08 | 103,574 | $21.05 | $2.18M | 579,959 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2017-12-06 | 2017-12-08 | 12,467 | $20.84 | $259.8K | 683,533 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | S Sale | 2017-12-06 | 2017-12-08 | 99,033 | $20.28 | $2.01M | 696,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award | 2017-06-01 | 2017-06-05 | 8,400 | $11.95 | $100.4K | 795,033 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | A Award deriv | 2017-01-06 | 2017-01-10 | 270,000 | — | $0 | 270,000 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | C Conversion deriv | 2016-05-11 | 2016-05-11 | 675,883 | — | $0 | 0 | SEC↗ |
| NTLA Intellia Therapeutics, Inc | C Conversion | 2016-05-11 | 2016-05-11 | 437,019 | — | $0 | 786,633 | SEC↗ |